{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:28:46Z","timestamp":1784834926192,"version":"3.55.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000085","name":"Ontario HIV Treatment Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000085","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Since 2016, over 50,928 people have died of an opioid-related overdose in Canada. The unregulated supply of drugs is increasingly toxic and volatile, and fentanyl from unregulated, street-based markets is driving this epidemic. Concerns that existing overdose prevention approaches were insufficient to address the rising number of overdoses led to the implementation of safer supply programs (SSPs) in Canada. SSPs provide prescribed medications to people who use drugs and are designed for individuals at high risk of overdose for whom existing care options have been ineffective or inappropriate. Evidence of SSP impact is growing but implementation processes, including admissions, are not well understood nor well-described in practice guidelines. Our purpose was to describe how the admission processes of four Ontario SSPs evolved and how these changes influenced program reach and perceived effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>During 2021, we conducted short demographic and semi-structured interviews with healthcare providers (n\u2009=\u200921) from four SSPs in Ontario about implementation processes, challenges, and impacts. Thematic analysis of data concerning admission processes was conducted in MAXQDA and descriptive statistics in SPSSv28.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Although the desire was for SSPs to have a broad reach, programs quickly realized they needed to develop strategies to manage the high demand for their programs. To manage this demand, strategies were implemented like waitlists, which were later replaced by points-based admission criteria. These admission criteria evolved over time, leading to a client population with high medical and social needs. The combination of high-acuity clients, limited capacity, and funding constraints, exacerbated by COVID-19, caused significant distress and burnout among service providers, prompting further changes to the SSPs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The implementation of SSPs in Ontario highlights the challenges of addressing intersecting public health emergencies in a resource-constrained healthcare system. SSPs, were adaptive and evolved in real time; while these adaptations addressed significant equity gaps, they also underscored the limitations of operating within an under-funded primary care model. The narrowing of admission criteria, necessitated by overwhelming demand and limited resources, ultimately constrained their reach and potential population-level impact.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-025-01344-3","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:03:48Z","timestamp":1764173028000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A sea of need: provider accounts of strategies used to manage admission demands to safer opioid supply programs in Ontario"],"prefix":"10.1186","volume":"22","author":[{"given":"Carol","family":"Strike","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Rudzinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose A.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Kolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kryszajtys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Guta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"1344_CR1","unstructured":"Health. S-rOaMSTGobotCoCMOo. Opioid- and stimulant-related harms in Canada Ottawa: Public Health Agency of Canada; 2025 [updated March, 2025. Available from: https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/."},{"key":"1344_CR2","unstructured":"Gomes T, Murray R, Kolla G, Leece P, Bansal S, Besharah J, et al. Changing circumstances surrounding opioid-related deaths in Ontario during the COVID-19 pandemic. Toronto, ON: The Ontario drug policy research network, the office of the chief coroner for Ontario\/ Ontario Forensic Pathology Service, Public Health Ontario; 2021."},{"issue":"1","key":"1344_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12954-025-01189-w","volume":"22","author":"B Wallace","year":"2025","unstructured":"Wallace B, Shkolnikov I, Kielty C, Robinson D, Gozdzialski L, Jai J, et al. Is fentanyl in everything? Examining the unexpected occurrence of illicit opioids in British Columbia\u2019s drug supply. Harm Reduct J. 2025;22(1):28.","journal-title":"Harm Reduct J"},{"key":"1344_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.104751","volume":"138","author":"P Gonzalez-Nieto","year":"2025","unstructured":"Gonzalez-Nieto P, Wallace B, Kielty C, Gruntman K, Robinson D, Substance S, et al. Not just fentanyl: understanding the complexities of the unregulated opioid supply through results from a drug checking service in British Columbia. Can Int J Drug Policy. 2025;138:104751.","journal-title":"Can Int J Drug Policy"},{"issue":"3","key":"1344_CR5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/dar.13580","volume":"42","author":"H Crepeault","year":"2023","unstructured":"Crepeault H, Socias ME, Tobias S, Lysyshyn M, Custance A, Shapiro A, et al. Examining fentanyl and its analogues in the unregulated drug supply of British Columbia, Canada using drug checking technologies. Drug Alcohol Rev. 2023;42(3):538\u201343.","journal-title":"Drug Alcohol Rev"},{"key":"1344_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2024.110810","volume":"133\u2013134","author":"JJ Miller","year":"2024","unstructured":"Miller JJ, Yazdanpanah M, Colantonio DA, Beriault DR, Delaney SR. New psychoactive substances: a Canadian perspective on emerging trends and challenges for the clinical laboratory. Clin Biochem. 2024;133\u2013134:110810.","journal-title":"Clin Biochem"},{"issue":"1","key":"1344_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12954-023-00867-x","volume":"20","author":"DT Zhu","year":"2023","unstructured":"Zhu DT. Public health impact and harm reduction implications of xylazine-involved overdoses: a narrative review. Harm Reduct J. 2023;20(1):131.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1344_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-018-0271-5","volume":"15","author":"M-LW Kinshella","year":"2018","unstructured":"Kinshella M-LW, Gauthier T, Lysyshyn M. Rigidity, dyskinesia and other atypical overdose presentations observed at a supervised injection site, Vancouver, Canada. Harm Reduct J. 2018;15(1):64.","journal-title":"Harm Reduct J"},{"key":"1344_CR9","unstructured":"Government of Canada. Safer supply. 2023."},{"key":"1344_CR10","doi-asserted-by":"publisher","DOI":"10.17269\/s41997-025-01006-8","author":"K Fajber","year":"2025","unstructured":"Fajber K, Sereda A, Warren S, Morris C, Nash G, Pauly B, et al. Comprehensive substance use services within primary care settings: the safer Opioid supply program at London intercommunity health centre. Can J Public Health. 2025. https:\/\/doi.org\/10.17269\/s41997-025-01006-8.","journal-title":"Can J Public Health"},{"issue":"3","key":"1344_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229713","volume":"15","author":"C Strike","year":"2020","unstructured":"Strike C, Robinson S, Guta A, Tan DH, O\u2019Leary B, Cooper C, et al. Illicit drug use while admitted to hospital: patient and health care provider perspectives. PLoS ONE. 2020;15(3):e0229713.","journal-title":"PLoS ONE"},{"key":"1344_CR12","unstructured":"Canadian association of people who use drugs. Safe supply: Concept Document 2019."},{"issue":"3","key":"1344_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/10282580701526088","volume":"10","author":"AD Hathaway","year":"2007","unstructured":"Hathaway AD, Rossiter K. Medical marijuana, community building, and Canada\u2019s compassionate societies 1. Contemp Justice Rev. 2007;10(3):283\u201396.","journal-title":"Contemp Justice Rev"},{"key":"1344_CR14","unstructured":"Lune H. Urban action networks: HIV\/AIDS and community organizing in New York City: Rowman & Littlefield; 2007."},{"issue":"8","key":"1344_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa0810635","volume":"361","author":"E Oviedo-Joekes","year":"2009","unstructured":"Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777\u201386.","journal-title":"N Engl J Med"},{"issue":"5","key":"1344_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1001\/jamapsychiatry.2016.0109","volume":"73","author":"E Oviedo-Joekes","year":"2016","unstructured":"Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial. JAMA Psychiat. 2016;73(5):447\u201355.","journal-title":"JAMA Psychiat"},{"issue":"7","key":"1344_CR17","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1111\/add.14171","volume":"113","author":"N Bansback","year":"2018","unstructured":"Bansback N, Guh D, Oviedo-Joekes E, Brissette S, Harrison S, Janmohamed A, et al. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. Addiction. 2018;113(7):1264\u201373.","journal-title":"Addiction"},{"issue":"36","key":"1344_CR18","doi-asserted-by":"publisher","first-page":"E1233","DOI":"10.1503\/cmaj.220892","volume":"194","author":"T Gomes","year":"2022","unstructured":"Gomes T, Kolla G, McCormack D, Sereda A, Kitchen S, Antoniou T. Clinical outcomes and health care costs among people entering a safer opioid supply program in Ontario. Can Med Assoc J. 2022;194(36):E1233\u201342.","journal-title":"Can Med Assoc J"},{"key":"1344_CR19","unstructured":"McMurchy D, Palmer R. Assessment of the implementation of safer supply pilot projects. 2022."},{"key":"1344_CR20","doi-asserted-by":"crossref","unstructured":"Schmidt RA, Guta A, Rai N, Sereda A, O\u2019Reilly E, Hales J, et al. Opioid Supply Programs: Hydromorphone prescribing in Ontario as a harm-reduction intervention to combat the drug poisoning crisis. Can J Public Health. 2024.","DOI":"10.17269\/s41997-024-00979-2"},{"key":"1344_CR21","unstructured":"Niazi A. Family medicine for all: Community health centres serve their neighbours, but capacity issues remain: CBC Radio; 2023."},{"key":"1344_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103601","volume":"102","author":"S Young","year":"2022","unstructured":"Young S, Kolla G, McCormack D, Campbell T, Leece P, Strike C, et al. Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada. Int J Drug Policy. 2022;102:103601.","journal-title":"Int J Drug Policy"},{"key":"1344_CR23","unstructured":"Government of Canada approves new treatment options for opioid use disorder and supports research, treatment and harm reduction projects in Ontario [press release]. Toronto, ON: The Government of Canada2019."},{"key":"1344_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104157","volume":"120","author":"M Karamouzian","year":"2023","unstructured":"Karamouzian M, Rafat B, Kolla G, Urbanoski K, Atkinson K, Bardwell G, et al. Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: a qualitative analysis. Int J Drug Policy. 2023;120:104157.","journal-title":"Int J Drug Policy"},{"key":"1344_CR25","unstructured":"Ontario Drug Policy Research Network. Safer opioid supply: a rapid review of the evidence. 2023."},{"key":"1344_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109440","volume":"235","author":"TD Brothers","year":"2022","unstructured":"Brothers TD, Leaman M, Bonn M, Lewer D, Atkinson J, Fraser J, et al. Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness. Drug Alcohol Depend. 2022;235:109440.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1344_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12954-022-00614-8","volume":"19","author":"B Lew","year":"2022","unstructured":"Lew B, Bodkin C, Lennox R, O\u2019Shea T, Wiwcharuk G, Turner S. The impact of an integrated safer use space and safer supply program on non-fatal overdose among emergency shelter residents during a COVID-19 outbreak: a case study. Harm Reduct J. 2022;19(1):29.","journal-title":"Harm Reduct J"},{"issue":"19","key":"1344_CR28","doi-asserted-by":"publisher","first-page":"E668","DOI":"10.1503\/cmaj.221550","volume":"195","author":"G Bardwell","year":"2023","unstructured":"Bardwell G, Ivsins A, Mansoor M, Nolan S, Kerr T. Safer opioid supply via a biometric dispensing machine: a qualitative study of barriers, facilitators and associated outcomes. Can Med Assoc J. 2023;195(19):E668\u201376.","journal-title":"Can Med Assoc J"},{"issue":"1","key":"1344_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12954-023-00776-z","volume":"20","author":"M Haines","year":"2023","unstructured":"Haines M, O\u2019Byrne P. Safer opioid supply: qualitative program evaluation. Harm Reduct J. 2023;20(1):53.","journal-title":"Harm Reduct J"},{"key":"1344_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108202","volume":"216","author":"A Ivsins","year":"2020","unstructured":"Ivsins A, Boyd J, Mayer S, Collins A, Sutherland C, Kerr T, et al. Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study. Drug Alcohol Depend. 2020;216:108202.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1344_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11524-020-00489-9","volume":"98","author":"A Ivsins","year":"2021","unstructured":"Ivsins A, Boyd J, Mayer S, Collins A, Sutherland C, Kerr T, et al. It\u2019s helped me a lot, just like to stay alive\u201d: a qualitative analysis of outcomes of a novel hydromorphone tablet distribution program in Vancouver, Canada. J Urban Health. 2021;98(1):59\u201369.","journal-title":"J Urban Health"},{"issue":"S2","key":"1344_CR32","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.2105\/AJPH.2021.306692","volume":"112","author":"R McNeil","year":"2022","unstructured":"McNeil R, Fleming T, Mayer S, Barker A, Mansoor M, Betsos A, et al. Implementation of safe supply alternatives during intersecting COVID-19 and overdose health emergencies in British Columbia, Canada, 2021. Am J Public Health. 2022;112(S2):S151\u20138.","journal-title":"Am J Public Health"},{"key":"1344_CR33","doi-asserted-by":"crossref","unstructured":"Schmidt RA, Kaminski N, Kryszajtys DT, Rudzinski K, Perri M, Guta A, et al. \u2018I don't chase drugs as much anymore, and I'm not dead\u2019: Client reported outcomes associated with safer opioid supply programs in Ontario, Canada. Drug and alcohol Review. 2023.","DOI":"10.1111\/dar.13745"},{"key":"1344_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-023-00817-7","author":"M Gagnon","year":"2023","unstructured":"Gagnon M, Rudzinski K, Guta A, Schmidt RA, Kryszajtys DT, Kolla G, et al. Impact of safer supply programs on injection practices: client and provider experiences in Ontario, Canada. Harm Reduct J. 2023. https:\/\/doi.org\/10.1186\/s12954-023-00817-7.","journal-title":"Harm Reduct J"},{"key":"1344_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076336","volume":"384","author":"A Slaunwhite","year":"2024","unstructured":"Slaunwhite A, Min JE, Palis H, Urbanoski K, Pauly B, Barker B, et al. Effect of risk mitigation guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study. BMJ. 2024;384:e076336.","journal-title":"BMJ"},{"key":"1344_CR36","unstructured":"Atkinson KT. Parkdale Queen West community health centre safer Opioid supply program evaluation Report. 2023."},{"key":"1344_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076336","author":"A Slaunwhite","year":"2024","unstructured":"Slaunwhite A, Min JE, Palis H, Urbanoski K, Pauly B, Barker B, et al. Effect of risk mitigation guidance for opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study. BMJ. 2024. https:\/\/doi.org\/10.1136\/bmj-2023-076336.","journal-title":"BMJ"},{"key":"1344_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckab164.803","author":"K Skivington","year":"2021","unstructured":"Skivington K, Craig P, Moore L, Matthews L, Simpson S. Introduction to the complex intervention concept and the research perspectives. Eur J Public Health. 2021. https:\/\/doi.org\/10.1093\/eurpub\/ckab164.803.","journal-title":"Eur J Public Health"},{"key":"1344_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckab164.804","author":"P Craig","year":"2021","unstructured":"Craig P, Skivington K, Moore L, Simpson S, Matthews L. The new framework and the core elements of complex intervention research. Eur J Public Health. 2021. https:\/\/doi.org\/10.1093\/eurpub\/ckab164.804.","journal-title":"Eur J Public Health"},{"key":"1344_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2019.112488","volume":"238","author":"T Rhodes","year":"2019","unstructured":"Rhodes T, Lancaster K. Evidence-making interventions in health: a conceptual framing. Soc Sci Med. 2019;238:112488.","journal-title":"Soc Sci Med"},{"key":"1344_CR41","unstructured":"Goyer M-E, Hudon K, Plessis-B\u00e9lair M-C, Ferguso Y. Substance replacement therapy in the context of the COVID-19 pandemic in Qu\u00e9bec: clinical guidance for prescribers. 2020."},{"key":"1344_CR42","unstructured":"Hales J, Kolla G, Man T, O\u2019Reilly E, Rai N, Sereda A. Safer opioid supply programs (SOS): a harm reduction informed guiding document for primary care teams-April 2020 update. 2020."},{"key":"1344_CR43","unstructured":"British Columbia Centre on Substance Use. Risk mitigation in the context of dual public health emergencies. 2020."},{"issue":"9","key":"1344_CR44","doi-asserted-by":"publisher","first-page":"E247","DOI":"10.1503\/cmaj.170958","volume":"190","author":"JMDM Bruneau","year":"2018","unstructured":"Bruneau JMDM, Goyer M-\u00c8MDM, Ahamad KMD, Poulin GMD, Selby PMM, Fischer BP, et al. Management of opioid use disorders: a national clinical practice guideline. Can Med Assoc J. 2018;190(9):E247\u201357.","journal-title":"Can Med Assoc J"},{"key":"1344_CR45","unstructured":"CPSO. Advice to the profession: Prescribing drugs. 2020."},{"key":"1344_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1258","volume":"350","author":"GF Moore","year":"2015","unstructured":"Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions: Medical Research Council guidance. BMJ. 2015;350:h1258-h.","journal-title":"BMJ"},{"issue":"1","key":"1344_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-4-50","volume":"4","author":"LJ Damschroder","year":"2009","unstructured":"Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4(1):50.","journal-title":"Implement Sci"},{"issue":"2","key":"1344_CR48","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1037\/a0022284","volume":"25","author":"LJ Damschroder","year":"2011","unstructured":"Damschroder LJ, Hagedorn HJ. A guiding framework and approach for implementation research in substance use disorders treatment. Psychol Addict Behav. 2011;25(2):194\u2013205.","journal-title":"Psychol Addict Behav"},{"key":"1344_CR49","volume-title":"Thematic analysis : a practical guide","author":"V Braun","year":"2021","unstructured":"Braun V, Clarke V. Thematic analysis\u202f: a practical guide. London: SAGE Publications Ltd; 2021."},{"key":"1344_CR50","volume-title":"The coding manual for qualitative researchers","author":"J Saldana","year":"2021","unstructured":"Saldana J. The coding manual for qualitative researchers. London: SAGE Publications Ltd; 2021."},{"issue":"1","key":"1344_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12954-023-00775-0","volume":"20","author":"T Austin","year":"2023","unstructured":"Austin T, Lavalley J, Parusel S, Collins AB, Olding M, Boyd J. Women who use drugs: engagement in practices of harm reduction care. Harm Reduct J. 2023;20(1):49.","journal-title":"Harm Reduct J"},{"issue":"S2","key":"1344_CR52","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.2105\/AJPH.2022.306776","volume":"112","author":"J Boyd","year":"2022","unstructured":"Boyd J, Maher L, Austin T, Lavalley J, Kerr T, McNeil R. Mothers who use drugs: closing the gaps in harm reduction response amidst the dual epidemics of overdose and violence in a Canadian urban setting. Am J Public Health. 2022;112(S2):S191\u20138.","journal-title":"Am J Public Health"},{"key":"1344_CR53","unstructured":"Kolla G, Fajber K. Safer opioid supply program evaluation: a comparison of SOS client outcomes from 2022 and 2023. London, ON: London Intercommunity Health Center; 2023."},{"key":"1344_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103849","volume":"110","author":"B Pauly","year":"2022","unstructured":"Pauly B, McCall J, Cameron F, Stuart H, Hobbs H, Sullivan G, et al. A concept mapping study of service user design of safer supply as an alternative to the illicit drug market. Int J Drug Policy. 2022;110:103849.","journal-title":"Int J Drug Policy"},{"key":"1344_CR55","doi-asserted-by":"crossref","unstructured":"Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, et al. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. BMJ (Online). 2021;374:n2061-n.","DOI":"10.1136\/bmj.n2061"},{"key":"1344_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104423","volume":"127","author":"L Michaud","year":"2024","unstructured":"Michaud L, Kolla G, Rudzinski K, Guta A. Mapping a moral panic: news media narratives and medical expertise in public debates on safer supply, diversion, and youth drug use in Canada. Int J Drug Policy. 2024;127:104423.","journal-title":"Int J Drug Policy"},{"key":"1344_CR57","doi-asserted-by":"crossref","unstructured":"Olding M, Rudzinski K, Schmidt R, Kolla G, German D, Sereda A, et al. Perspectives on diversion of medications from safer opioid supply programs. JAMA Network Open. 2024;7(12):e2451988-e.","DOI":"10.1001\/jamanetworkopen.2024.51988"},{"key":"1344_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.104731","volume":"137","author":"M Haines","year":"2025","unstructured":"Haines M, Hill E, O\u2019Byrne P. Safer supply programs: discussions on medication diversion, sharing, and selling. Int J Drug Policy. 2025;137:104731.","journal-title":"Int J Drug Policy"},{"key":"1344_CR59","doi-asserted-by":"crossref","unstructured":"Ivsins A, Christy S, Thomas K, and Kennedy MC. Early experiences and impacts of a fentanyl powder safer supply program in Vancouver, Canada: a qualitative study. Am J Drug Alcohol Abuse. 2025;1\u201310.","DOI":"10.1016\/j.drugalcdep.2024.111501"},{"key":"1344_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104600","volume":"133","author":"P Wilson","year":"2024","unstructured":"Wilson P, Colizza K, Hyshka E. Safer supply and political interference in medical practice: Alberta\u2019s narcotics transition services. Int J Drug Policy. 2024;133:104600.","journal-title":"Int J Drug Policy"},{"key":"1344_CR61","unstructured":"Ontario protecting communities and supporting addiction recovery with new treatment hubs [press release]. 2024."},{"key":"1344_CR62","unstructured":"Talbot M. Doug ford calls federal government the \u2018biggest drug dealer\u2019 in Canada for providing addicts with safer drug supplies. CityNews. 2024 Augst 21, 2024."},{"key":"1344_CR63","unstructured":"Drug User Liberation Front. Drug user liberation front: a brief history. 2023."},{"key":"1344_CR64","unstructured":"Woo A. B.C. rejects coroner panel\u2019s call to expand access to safer-supply program. The Globe and Mail. 2023."},{"key":"1344_CR65","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.drugpo.2016.01.002","volume":"30","author":"T Rhodes","year":"2016","unstructured":"Rhodes T, Closson EF, Paparini S, Guise A, Strathdee S. Towards, \u201cevidence-making intervention\u201d approaches in the social science of implementation science: the making of methadone in East Africa. Int J Drug Policy. 2016;30:17\u201326.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1344_CR66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12954-024-00935-w","volume":"21","author":"G Kolla","year":"2024","unstructured":"Kolla G, Tarannum CN, Fajber K, Worku F, Norris K, Long C, et al. Substance use care innovations during COVID-19: barriers and facilitators to the provision of safer supply at a Toronto COVID-19 isolation and recovery site. Harm Reduct J. 2024;21(1):17.","journal-title":"Harm Reduct J"}],"updated-by":[{"DOI":"10.1186\/s12954-026-01473-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000}}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01344-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01344-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01344-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:36:59Z","timestamp":1780292219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-025-01344-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1344"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01344-3","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"28 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The author David Kryszajits name has been updated to David Kryszajtys in the article PDF.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12954-026-01473-3","URL":"https:\/\/doi.org\/10.1186\/s12954-026-01473-3","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the University of Toronto Research Ethics Board (Protocol: 40140). All participants verbally consented to participate in the interview.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Separate from this study, Dr. Kolla received funding from London InterCommunity Health Centre\u2019s Substance Use and Addictions Program grant to conduct an independent preliminary evaluation of their Safer Opioid Supply program. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"194"}}